Featured Research

from universities, journals, and other organizations

Human guinea pigs wary of high-paying medical trials

Date:
December 7, 2009
Source:
Washington University in St. Louis
Summary:
New research shows that people equate large payments for participation in medical research with increased levels of risk. And when they perceive studies to be risky, they spend more time learning about the risks and nature of the study. Paper published this month in Social Science and Medicine suggests there is a "mismatch" between current research guidelines for setting compensation levels and the assumptions participants make about the levels of pay and risk.

More than 15 million Americans are recruited annually to participate in clinical trials according to the Alliance for Human Research Protection (AHRP), and most will be compensated for their participation.

Research institutions view payments to volunteers as compensation for time and expenses; not as compensation for potential risks related to participating in the experiments. A new study finds that volunteers have a very different view of clinical trial compensation. High-paying research studies raise a red flag for human guinea pigs and signal high levels of risk.

The findings from a study published in December by the journal Social Science and Medicine have implications for informed consent in human subjects research and the debate over research participation incentives.

Cynthia Cryder, assistant professor of Marketing at the Olin Business School, Washington University in St. Louis, is the lead author of the study, "Informative Inducement: Study Payment as a Signal of Risk"*. Her co-authors are Alex John London and George Loewenstein at Carnegie Mellon University and Kevin G. Volpp at the University of Pennsylvania School of Medicine and the Wharton School.

"At a big-picture level, what stands out from these results is that research participants do not just consider participation payments as an incentive to be traded off for their time." Cryder explains. "They actually infer information about the study itself from the participation payment."

Cryder and colleagues conducted three experiments to measure people's interest in participating in potentially risky research studies, their perception of the risk associated with those studies and how payment amounts affected their interest and perceptions.

Experiments for the study were conducted with an online nationwide sample or a sample from a northeastern U.S. city in 2007-2008.

The study finds that while high pay is a real incentive for people to participate in clinical trials, it also increases the "perceived risk" of the trial and the time potential volunteers spend researching and viewing information about risks related to the trial.

"Specifically in our experiments," Cryder explains, "they [participants] judge studies that offer high payments to be riskier than identical studies that offer low payments."

George Loewenstein, the Herbert A. Simon Professor of Economics and Psychology at Carnegie Mellon and co-author of the study, says these findings contradict some of the common guidelines used for establishing participation incentives:

"Most organizations that do research prohibit participation payments that substantially exceed compensation for time and expenses. The fear is that people will be overly tempted by high payments to take excessive risks. Our research challenges this common practice. It suggests that people assume that studies that don't pay much aren't risky."

The study concludes that there is a "mismatch" between current research guidelines for setting compensation levels and the assumptions participants make about the levels of pay and risk. Loewenstein explains:

"Contrary to the assumption that high payments are excessively tempting, our research suggests that they alert subjects to potential risk and make them more vigilant about protecting themselves. An added bonus of high payments is that it is ethically sensible for people to be adequately compensated when they do, in fact, incur risks."

The authors of the study believe their findings should contribute to the debate over research participation incentives and informed consent. The way potential human subjects interpret payment, risk and information about clinical trials as documented in the Cryder et al paper sheds new light on the role of the human subjects in research.


Story Source:

The above story is based on materials provided by Washington University in St. Louis. Note: Materials may be edited for content and length.


Journal Reference:

  1. E. Cryder et al. Informative inducement: Study payment as a signal of risk. Social Science & Medicine, 2009; DOI: 10.1016/j.socscimed.2009.10.047

Cite This Page:

Washington University in St. Louis. "Human guinea pigs wary of high-paying medical trials." ScienceDaily. ScienceDaily, 7 December 2009. <www.sciencedaily.com/releases/2009/12/091206112521.htm>.
Washington University in St. Louis. (2009, December 7). Human guinea pigs wary of high-paying medical trials. ScienceDaily. Retrieved August 23, 2014 from www.sciencedaily.com/releases/2009/12/091206112521.htm
Washington University in St. Louis. "Human guinea pigs wary of high-paying medical trials." ScienceDaily. www.sciencedaily.com/releases/2009/12/091206112521.htm (accessed August 23, 2014).

Share This




More Health & Medicine News

Saturday, August 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Two US Ebola Patients Leave Hospital Free of the Disease

Two US Ebola Patients Leave Hospital Free of the Disease

AFP (Aug. 21, 2014) Two American missionaries who were sickened with Ebola while working in Liberia and were treated with an experimental drug are doing better and have left the hospital, doctors say on August 21, 2014. Duration: 01:05 Video provided by AFP
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins